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Background: Levothyroxine sodium (LT4) is the therapy of choice for hypothyroidism. 
In the last decade, new LT4 formulations, such as liquid and softgel capsules, became 
available. Even if some evidence has been reached in the efficacy of liquid LT4 in patients 
with suboptimal TSH on tablet LT4, the usefulness of softgel LT4 has been rarely stud-
ied. This study aimed at evaluating the effect of switching from tablet to softgel LT4 
patients without increased need for LT4. TSH was used as proxy of LT4 bioavailability 
and effectiveness.
Methods: During the period from April to August 2017, 19 patients on tablet LT4 treat-
ment for hypothyroidism, mostly due to autoimmune thyroiditis, were enrolled. Subjects 
with causes of malabsorption or increased requirement of LT4 were previously excluded. 
Patients finally included were asked to switch from tablet to softgel LT4 formulation at 
unchanged dose and ingestion fashion (30 min before breakfast). TSH was measured 
with chemiluminescence immunoassays.
results: According to exclusion and inclusion criteria, 19 patients were finally selected. 
One of these had headache 4 days later and come back to tablet LT4, and 18 of them 
(16W/2M; mean age =  55  years; BMI 22.7  kg/m2) completed the study. They were 
treated with a median LT4 dose of 88  μg/day and showed a median TSH value of 
3.33 mIU/L. The rate of cases with TSH ≤ 4.0 mIU/L was 61.1% (11/18 cases). When 
patients were re-evaluated after 3 months of softgel LT4, we observed that TSH reached 
levels under 4.0 mIU/L in 16/18 (88.9%) patients, TSH was lower in 11 cases, and in 6 
out of 7 patients with pre-switch TSH values over the normal range. Overall, TSH values 
on softgel LT4 (median 1.90 mIU/L) was significantly lower from that observed during 
tablet LT4 (p = 0.0039).
conclusion: These data show that hypothyroid patients with no proven malabsorption 
may have an improved TSH following 3 months from the switch from tablet to softgel LT4 
preparation at unchanged dose.
Keywords: hypothyroidism, thyroxine absorption, softgel, levothyroxine, drugs dissolution
FigUre 1 | Diagram of the study design. In the enrollment phase, TSH was 
measured two times (−3 and 0 months). Patients were enrolled if the second 
value was similar to the first one. At 0 time point, all included patients were 
switched to softgel LT4 at unchanged dose. Following 3 months, TSH were 
re-evaluated and compared to the pre-switch value (the pre-switch value 
used has been the last one obtained).
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inTrODUcTiOn
Levothyroxine sodium (LT4) is the therapy of choice for 
hypothyroidism (1), and the tablet LT4 is the most widely used 
preparation worldwide. The absorption of tablet LT4 prepara-
tion requires disintegration of the tablet and dissolution of the 
particles of active ingredient (2). These events are preconditions 
for an effective absorption of the hormone, which takes place 
in the small intestine (3). Its narrow therapeutic index and the 
deleterious effects of chronic over- and under-treatment render 
mandatory a fine calibration of LT4 dose (4); also, the large 
number of factors interfering with LT4 treatment efficacy leads, 
even nowadays, to the existence of a significant amount of treated 
patients showing TSH levels outside the therapeutic target (5). 
In fact, bioavailability of levothyroxine may be affected by 
several physiological and pathological conditions: specific habits 
such as dietary fiber, soy, and coffee concomitant ingestion, 
widespread gastrointestinal diseases such as Helicobacter pylori, 
atrophic gastritis, celiac disease, lactose intolerance, dysbiosis 
[see Ref. (6) for review], and widely prescribed drugs such as 
proton-pump inhibitors, aluminum-containing antacids, cal-
cium carbonate, ferrous sulfate, sucralfate, raloxifene, bile acid 
sequestrants, and phosphate binders (7).
In the last decade, new LT4 formulations, such as liquid 
mono-dose ampoules and softgel capsules, became available (8). 
A recent meta-analysis revealed that patients with suboptimal 
TSH on tablet LT4 can attain a better pharmacologic homeostasis 
(i.e., lower serum TSH) by switching to liquid LT4 formulation 
at unchanged dose (9). Unlike liquid LT4, the efficacy of softgel 
LT4 preparation has been less investigated (10). In particular, the 
usefulness of softgel LT4 has been prospectively studied only in 
series of 8 patients with coffee-related LT4 malabsorption (11), in 
31 patients with gastric diseases (12), and in 60 patients ingesting 
softgel capsule at breakfast (13); case reports also inquired into 
the efficacy of this therapeutic option in patients concomitantly 
treated with PPI (14), bearing gastroparesis (15) and with cen-
tral hypothyroidism (16). On the contrary, there are only two 
reports dealing with patients without interferences but one was 
retrospective (17) and the other evaluated the LT4 requirement 
in thyroidectomized patients (18). This study was designed to 
evaluate the potential effect of switching from tablet to softgel 
LT4, using serum TSH values as the main outcome. Therapeutic 
switch, at the same dose, involved patients certainly compliant 
with treatment without increased need for LT4.
MaTerials anD MeThODs
selection of Patients
According to the study aim, we enrolled hypothyroid patients on 
tablet LT4 therapy examined during the period from April 1 to 
August 31, 2017 (Enrollment Phase, see Figure 1). As inclusion 
criteria, patients must be hypothyroid in need for treatment with 
LT4 according to ATA Guidelines (1) due to autoimmune thy-
roiditis or total thyroidectomy for benign goiter. These patients 
were included regardless of their serum thyroid tests (i.e., serum 
TSH within the normal range or not) but showing serum TSH 
variations lesser than 1.0  mIU/L in two sequential control 
visits and they must be treated with LT4 in tablet formulation. 
We excluded patients with most of the described causes of mal-
absorption or increased requirement of LT4; then, were not enrolled 
patients with the following conditions either previous or active: 
presence and/or signs or symptoms suggestive for H. pylori-related 
gastritis (19), atrophic gastritis (20), celiac disease (21) or lactose 
intolerance (22), parasitic infestation (23), intestinal dysbiosis 
(24, 25), gastric, intestinal or bariatric surgery (26); pregnancy; 
concomitant treatment with PPIs, amiodarone, betablockers, 
lithium, raloxifene, interferons, cholestyramine, and antacids (7). 
We also looked for the presence of chronic unexplained anemia 
as sign of GI disorders (27). When only suspected for these 
conditions, patients underwent gastroenterological counseling. 
Finally, patients with neoplastic or chronic severe diseases were 
excluded because of the possibility of nonthyroidal illnesses. 
In all patients, according to the abovementioned criteria, we 
verified the compliance with LT4 therapy by specifically inter-
viewing patients at every control visit; patients with suspected 
poor adherence to therapy (e.g., fluctuating TSH values in the two 
controls during enrollment, inconsistent answers to interview, 
etc.) were excluded. Local Ethical Committee does not require 
specific process for studies in which the authors use retrospective 
data of patients in anonymous and grouped manner; according 
to these rules, patients were informed orally on their possibility 
to be excluded from the study (i.e., right to object).
study Design
All patients were asked to switch from tablet to softgel LT4 for-
mulation (Tirosint® capsules molles, IBSA Institute Biochimique 
SA, CH-6903 Lugano, Switzerland) at unchanged dose and inges-
tion fashion (30  min before breakfast). Serum reflex TSH was 
re-evaluated 3 months after the switch (Study Phase, Figure 1). 
The pre-switch TSH used for comparison with the post-switch 
TSH is the one at 0 time point.
FigUre 2 | Diagram of flow of search strategy and results.
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laboratory Measurement
Thyrotropin (TSH) was measured with chemiluminescence 
immu noassays (HYPERsensitive hTSH) on a UniCel DxI 800 auto-
mated platform (Beckman Coulter SA, Nyon, Switzerland). The 
HYPER sensitive hTSH assay is based on the third International 
Standard (WHO) for human TSH (IRP 81/565) with analytical 
sensitivity of 0.003 mIU/L, FS of 0.01 mIU/L, respectively. The 
TSH normal reference range is 0.40–4.00 mIU/L. Serum levels of 
free-T4 (normal range from 7.5 to 21.1 pmol/L), free-T3 (from 
3.8 to 6.0  pmol/L), and TSH (from 0.4 to 4.0 mIU/mL) were 
automatically measured only in presence of skewed TSH value.
statistical analysis
Value of TSH recorded on tablet and softgel LT4 were expressed 
as mean  ±  SD and compared by non-parametric statistical 
analysis for paired data (Wilcoxon test). Frequencies of patients 
with normal TSH with tablet and softgel LT4 were compared 
by chi square or Fisher’s exact test, when indicated. Statistical 
significance was set at p < 0.05. Statistical analysis was performed 
by GraphPad version 7 (GraphPad Prism, La Jolla CA, USA).
resUlTs
During the enrollment period, we examined 246 hypothyroid 
patients; among them, after initial selection, 19 (7.7%) patients 
met the inclusion criteria (Figure 2). All 19 patients were advised 
to switch from tablet to softgel LT4 at the same dose and with the 
same time schedule. One patient had headache four days later 
and come back to tablet LT4 with disappearance of headache. 
Then, 18 patients (16 females and 2 males, mean age 55 years; 
BMI 22.7 ±  2.9  kg/m2; 14 of them bearing Hashimoto’s thy-
roiditis and 4 thyroidectomized for benign goiter) represented 
the study group which completed the study. These patients were 
treated with a mean LT4 dose of 95.2 ±  23.5 μg/day (median 
88 μg/day) and showed a mean TSH value of 3.65 ± 2.11 mIU/L 
(median 3.33 mIU/L, range from 0.54 to 8.03 mIU/L). The rate 
of patients with TSH within the normal reference range was 
61.1% (11/18 cases). Serum FT4 and FT3 in those patients with 
increased TSH were anyway in the normal range. All cases were 
re-evaluated after 3 months of softgel LT4 therapy. During this 
period, no significant changes of BMI values (23.1 ± 3.1 kg/m2) 
and no side effects were recorded. Three months after the switch, 
we observed that TSH reached levels under 4.0  mIU/L in all 
patients but two who showed a serum TSH slightly higher than 
upper reference value (4.06 and 4.69 mIU/L) while in 3 patients, 
TSH was even lower than the reference range (0.10, 0.31, and 
0.34  mIU/L). Normal free-T3 and free-T4 levels were again 
observed in all patients with TSH outside the normal range. Serum 
TSH was lower than the one before switch in 11 patients, similar 
in 5, including the two patients with serum TSH over 4.0 mIU/L, 
and higher in just one. Six out of seven patients with pre-switch 
TSH values over the normal range showed a lowered post-switch 
TSH value, in five of them lower than 4.0 mIU/L (Figure 3A).
Therefore, the number of patients with TSH lower than 
4.0  mIU/L after the switch to softgel was 16/18 (88.9%); TSH 
values (mean 1.93 ± 1.36 mIU/L, median 1.90 mIU/L, range from 
0.10 to 4.69  mIU/L) were significantly different from the one 
observed when patients were treated with tablet LT4 (p = 0.0039) 
being the mean difference 1.72 mIU/L (Figure 3B).
DiscUssiOn
Several studies have shown that the absorption of LT4 in tablet 
formulation is impaired in various conditions such as gastric 
disorders, intestinal malabsorption, or drug interference, and 
this may be improved, in some cases, by switching to liquid LT4 
preparation (9, 10). In addition, some studies showed that switch-
ing from tablet to liquid LT4 improved TSH levels of hypothyroid 
patients also in the absence of significant pathophysiological biases 
(28, 29). Furthermore, the study by Di Donna et al. demonstrated 
that LT4 requirement in tablet and softgel formulation is the same 
in thyroidectomized patients without malabsorption, despite 
a slightly reduced median TSH value in patients treated with 
softgel formulation (18). Here, we selected hypothyroid patients, 
mostly bearing Hashimoto’s thyroiditis, under levothyroxine 
therapy and without an increased need for thyroxine showing 
FigUre 3 | (a) Effect on TSH levels of switch from tablet to softgel LT4 preparation at the same dose in patient with TSH above 4.0 mIU/L; (B) Effect on TSH  
of switch from tablet to softgel LT4 preparation in the whole study series.
4
Trimboli et al. Softgel Levothyroxine
Frontiers in Endocrinology | www.frontiersin.org March 2018 | Volume 9 | Article 118
that the use of softgel LT4 significantly improved TSH values. 
Overall, lower TSH values were recorded in 4/5 of our patients 
and unchanged in the remaining. Owing to the role of gastric acid 
secretion on the process of T4 absorption (30), we may speculate 
that this finding may be due to the interindividual variation of 
gastric acidic output, even in gastric unaffected patients. A semi-
nal pharmacokinetic study published in 2009 (31), has clearly 
established, in vitro, that softgel LT4 shows a better dissolution 
profile, at increasing pH values, as compared to tablet formula-
tion. In vivo, using a single massive dose of 600 µg of labeled T4, 
softgel preparation, bioequivalent to tablet LT4 in fasting healthy 
volunteers, performed better than traditional formulation in 
patients with increased gastric pH (32). Moreover, this evidence 
has been clinically confirmed in patients with gastric diseases, in 
which target TSH had been reached with a reduced dose (−17%) 
in two-thirds of patients (12). The efficacy of this formulation has 
been also proven in patients with increased need for LT4 due to 
concomitant ingestion of coffee (11).
This study should have some limitations: first, we evaluated 
the two preparations performances in the very same way, spac-
ing the drug and food or drink intake by 30 min, as suggested 
in the leaflet of tablet LT4. Evidence have been presented that 
this lag time may not interfere with the softgel preparation but 
may reduce significantly the absorption and then the effect of 
tablet T4 preparation (11, 33–37). This suggests the need for 
further studies, even with a more extended follow-up, in which 
all the parameters of thyroid pharmacological homeostasis are 
taken into account (i.e., comparing the efficacy of the two drugs 
by distancing at least an hour the intake of the drug and food). 
The consolidated habit, in both patients and physicians, to use 
a lag time of only 30 min before having breakfast prevented us 
from variating this schedule in the present study. Secondly, free-T4 
and free-T3 values were not available for all patients because of 
the use of reflex TSH in clinical practice.
cOnclUsiOn
These data show that hypothyroid patients with no proven mal-
absorption may have an improved TSH following 3 months from 
the switch from tablet to softgel LT4 preparation at unchanged 
dose. This evidence sheds light on the role that new formulations 
of levothyroxine can play to individualize the treatment in the era 
of precision medicine to limit the rate of patients with inadequate 
pharmacological thyroid homeostasis.
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